EYPT optimism rises as LUCIA trial secondary endpoints look strong
DURAVYU’s phase III LUGANO wet AMD trial missed its primary endpoint on randomization imbalance, but strong secondary endpoints, safety, and reduced injection burden support confidence for upcoming LUCIA results.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.